Saw Palmetto Claims Appeal Shot Down; Emord Eyes Supreme Court
This article was originally published in The Tan Sheet
Executive Summary
The Washington, D.C. federal appeals court upheld FDA's denial of a health claim petition linking saw palmetto extract to treatment of benign prostatic hypertrophyYou may also be interested in...
Class Action Feeding Frenzy Could Chill On Legislation, Judicial Shift
Food and supplement class action complaints could be slowed by legislation in Congress and by judges potentially de-emphasizing reliance on FDA interpretation of statutes, say lawyers during FDLI conference discussion.
FDA First Amendment Litigation: Will Amarin Case Break The Log Jam?
Courts have issued mixed rulings in cases challenging FDA restrictions on drug promotion, but with oral arguments set for July 7, Amarin’s suit could provide a definitive answer on what companies can tell physicians.
Saw Palmetto denial
High court refuses petitioners who requested the court review FDA's denial of a health claim linking saw palmetto to benign prostatic hyperplasia, law firm Emord & Associates says Oct. 12. Julian Whitaker, et al., filed the writ of certiorari earlier this year (1"The Tan Sheet" Jan. 19, 2004, p. 16)...
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: